Cantargia
4.10 SEK
-2.96 %
1,287 following
CANTA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Cantargia
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 316.7 | ||||||
| growth-% | |||||||
| EBITDA | -111.6 | -173.9 | -370.3 | -381.6 | -290.0 | -168.6 | 157.4 |
| EBIT | -111.6 | -173.9 | -370.3 | -381.6 | -290.0 | -168.6 | 154.1 |
| Profit before taxes | -110.8 | -173.1 | -366.5 | -371.8 | -280.0 | -161.7 | 147.0 |
| Net income | -110.8 | -173.1 | -366.5 | -371.8 | -280.0 | -161.7 | 147.0 |
| EPS | -1.27 | -1.44 | -3.04 | -2.90 | -1.65 | -0.88 | 0.59 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | 0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 49.7 % | ||||||
| EBIT-% | 48.7 % | ||||||
| ROE | -77.9 % | -19.4 % | -68.8 % | -95.4 % | -166.0 % | -139.0 % | 55.3 % |
| ROI | -66.7 % | -18.7 % | -61.1 % | -78.3 % | -125.2 % | -94.8 % | 49.5 % |